Therapy Areas: Infectious Diseases
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
15 July 2024 - Clinical stage biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP), a specialist in antibiotics for challenging bacterial infections, on Monday announced the presentation...
Technavio predicts increase in global peptide therapeutics market size
5 July 2024 - Technavio, a US-based global technology research and advisory company, announced on Thursday that the global peptide therapeutics market size is expected to increase by USD17.85bn from 2...
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
3 July 2024 - Biopharmaceutical company GSK plc (LSE/NYSE: GSK) and biotech firm CureVac N.V. (Nasdaq: CVAC) announced on Wednesday that they have restructured their collaboration into a new licensing...
P95 BV acquires 4Clinics
3 July 2024 - P95 BV ('P95'), a Belgium-based global company involved in clinical and epidemiology research solutions, with a focus on vaccines and infectious diseases, announced on Tuesday ...
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
1 July 2024 - Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday reported promising results from its Phase 2/3 COVA study of oral BIO101 (20-hydroxye...
SCG Cell Therapy's SCG142 IND application receives US FDA approval
1 July 2024 - SCG Cell Therapy Pte Ltd (SCG), a Singapore-based biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced on Sunday that it...